Thanks to our grassroots advocates, the Recalcitrant Cancer Research Act was signed by President Obama in January 2013. Since then, we have been monitoring implementation carefully and are pleased to report that the National Cancer Institute (NCI) has made some important progress, including releasing four key recommendations and taking specific steps toward implementing those recommendations.
|Understand the biological relationship between pancreatic cancer and diabetes
|Evaluate screening protocols for biomarkers for early detection of pancreatic cancer and its precursors
|NCI is expected to release a program announcement (a call for research proposals) by February 2015.
|Study new therapeutic strategies in immunotherapy
|An NCI-sponsored clinical trials network is actively negotiating with pharmaceutical companies to conduct clinical trials with the most promising immunotherapy agents in pancreatic cancer patients.
|Develop new treatment approaches that interfere with RAS oncogene-dependent signaling pathways